Related Experiment Videos
Effect of aclacinomycin on lipid peroxide levels in tissues of mice
Abstract:
We have examined the lipid peroxide levels in aclacinomycin (ACM)-treated mice by using adriamycin (ADR) as a comparative drug. There was no increase in the lipid peroxide level of the heart at either 3h or 4d after ACM administration (15 mg/kg, i.p.), although the level in the heart of ADR-treated mice was elevated to 257% of that in normal mice. The effect of ACM and its glycoside-type metabolites on the increase of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent microsomal lipid peroxidation (in vitro) was weaker than that of ADR. Then, we examined the tissue concentrations of ACM. The AUC0-24h of ACM was the lowest in the heart among the tissues examined, being only 29.3% of that obtained with ADR. However, the concentrations of the glycoside-type metabolites of ACM in all tissues determined were higher than the concentration of ACM. In the heart, the T1/2 and AUC0-24h of ACM glycosides were somewhat higher than those of ADR. In conclusion, ACM and its metabolites do not lead to an increase in lipid peroxide level in the heart of mouse, and the difference in lipid peroxide increment in the mouse heart induced by ADR and ACM is independent of the tissue concentration of the drugs.
Insights
Aclacinomycin (ACM) does not increase lipid peroxide levels in mouse hearts, unlike adriamycin (ADR). This study compares their cardiotoxicity, finding ACM safer regarding lipid peroxidation.
Area of Science:
- Pharmacology
- Cardiotoxicity
- Drug Metabolism
Background:
- Adriamycin (ADR) is known to cause cardiotoxicity, partly due to increased lipid peroxidation.
- Aclacinomycin (ACM) is an anthracycline antibiotic with potential cardiotoxic effects that require investigation.
- Understanding the mechanisms of cardiotoxicity is crucial for developing safer chemotherapeutic agents.
Purpose of the Study:
- To compare the effects of aclacinomycin (ACM) and adriamycin (ADR) on lipid peroxide levels in mouse hearts.
- To investigate the in vitro lipid peroxidation potential of ACM and its metabolites compared to ADR.
- To determine the tissue distribution and pharmacokinetics of ACM and its metabolites in relation to cardiotoxicity.
Main Methods:
- Measurement of lipid peroxide levels in mouse heart tissue at various time points after ACM and ADR administration.
- In vitro assessment of NADPH-dependent microsomal lipid peroxidation induced by ACM, its metabolites, and ADR.
- Quantification of ACM and its metabolite concentrations in various tissues using pharmacokinetic analysis (AUC, T1/2).
Main Results:
- ACM administration did not elevate heart lipid peroxide levels, whereas ADR significantly increased them (257% of control).
- ACM and its metabolites showed weaker in vitro lipid peroxidation effects compared to ADR.
- While ACM concentrations were lower in the heart than ADR, ACM glycoside metabolites had higher tissue concentrations and comparable or longer half-lives than ADR in the heart.
Conclusions:
- Aclacinomycin (ACM) and its metabolites do not induce an increase in heart lipid peroxide levels in mice.
- The observed difference in cardiotoxicity between ADR and ACM regarding lipid peroxidation is not solely dependent on tissue drug concentrations.
- ACM appears to have a potentially safer cardiac safety profile concerning lipid peroxidation compared to ADR.